Duarte, Luís MotaSantos, FábioSilva, Maria Do Mar De Freitas Morna Duarte2024-04-242024-04-242023-01-132023-01-10http://hdl.handle.net/10362/166561Medpace is one of the world’s leading Contract Research Organizations, by revenue, and it differentiates itself by focusing on full-service clinical trials for small and mid-sized biopharma clients. Its strong positioning in a niche market, the high projected industry growth, its strong and stable FCFs, and experienced management team make it an ideal target, which would be further improved by our developed business plan that will enhance its operations, expand internationally, and capitalize on M&A trends. Our proposed transaction is expected to deliver a money multiple of 3.28x and an IRR of 26.84%, representing a strong investment opportunity.engContract research organization (Cro)Research & development (R&D)Mergers & acquisitions (M&A)BiopharmaLeverage buyout (Lbo)Money Multiple (Mm)Internal rate of return (Irr)master thesis203363531